{"entity":{"id":"nct05557591","kind":"trial","name":"A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small ","aka":[],"tldr":"A phase 2 trial of Cemiplimab in non-small-cell lung cancer and small-cell lung cancer, run by Regeneron Pharmaceuticals, active and no longer recruiting.","summary":"A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1) is a phase 2 interventional study registered as NCT05557591 by Regeneron Pharmaceuticals, with 51 participants enrolled, started 2023-04-21 and due to reach its primary completion in 2028-01-26. Interventions recorded: BNT116, Cemiplimab. Conditions listed: Advanced Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05557591","url":"https://clinicaltrials.gov/study/NCT05557591"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc","pdl1-high-nsclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["cemiplimab"],"companies":["regeneron"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05557591","phase":"2","setting":"A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 ≥50%","sponsor":"Regeneron Pharmaceuticals","participation":[{"nct":"NCT05557591","source":"https://clinicaltrials.gov/study/NCT05557591","fetchedAt":"2026-10-07T16:53:45.224Z","studySha256":"4ec78f24fdbff7ecf2cdc656419edecb5a7a0c209c3386a6af9cae7d7c9b475a","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-05-06","leadSponsor":"Regeneron Pharmaceuticals","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":51,"enrolmentType":"ACTUAL","siteCount":52,"recruitingSiteCount":0,"countries":["Georgia","Germany","South Korea","Spain","Taiwan","Turkey (Türkiye)","United States"]}],"started":"2023-04-21","startedType":"actual","enrolled":51,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05557591/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pdl1-high-nsclc","kind":"cancer","name":"PD-L1-high non-small-cell lung cancer without a driver mutation","route":"/cancers/pdl1-high-nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"cemiplimab","kind":"drug","name":"Cemiplimab","route":"/drugs/cemiplimab/"}],"company":[{"id":"regeneron","kind":"company","name":"Regeneron","route":"/companies/regeneron/"}]}}